生物技术企业BriaCell Therapeutics宣布进行1500万美元股权融资后，其股价应声下挫。周二纳斯达克尾盘时段，该公司股价暴跌62%，报收0.78美元。值得关注的是，在融资消息公布前，该股日内多数时间维持在1.75至1.90美元区间震荡。
这家专注癌症治疗的生物科技公司披露，将以每股1.25美元的价格发行1200万个融资单位。每个单位包含一股普通股（或替代性的预付认股权证）及一份认股权证。市场对此融资方案反应强烈，导致股价出现断崖式下跌。
颇具戏剧性的是，就在融资公告发布同日早些时候，BriaCell刚宣布梅奥医学中心加入其核心抗癌药物Bria-IMT的临床研究项目。该研究旨在评估这款主导候选药物对晚期转移性乳腺癌的疗效。然而这项研发进展未能抵消融资消息对市场信心的冲击，投资者选择用脚投票引发股价剧烈波动。
此次股权融资的突然推进与研发利好的同期释放，形成鲜明对比。市场反应凸显投资者更关注股权稀释风险，而非研发管线进展。股价的深度回调反映出资本对生物科技企业融资行为的敏感度，尤其在当前波动市况中更为凸显。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.